In contrast, Caro-Cardon et al. [27] examined post-COVID-19 heart failure outcomes, finding a 27.5% incidence of new heart failure episodes and a 17.6% mortality rate among patients with either clinical heart failure or elevated NT-proBNP. This evidence concerns the gene NPPB and heart failure.